4 news items
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
, that may include but are not limited to statements regarding: the design, scope, conduct, continuation, completion, intended purpose, or future results
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
SAVA
8 May 24
proceeds for working capital and general corporate purposes, including continued development of simufilam, the Company's lead drug candidate
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
SAVA
1 May 24
protecting stockholders from excessive dilution; the design, scope, completion, intended purpose, or future results of our warrant distribution
Redemption Date Announced for Warrants
SAVA
15 Apr 24
, intended purpose, or future results of our warrant distribution; any expected clinical results of our on-going Phase 3 studies of simufilam
- Prev
- 1
- Next